A coordinated action of Bax, PUMA, and p53 promotes MG132-induced mitochondria activation and apoptosis in colon cancer cells

Wen Xing Ding, Hong Min Ni, Xiaoyun Chen, Jian Yu, Lin Zhang, Xiao-Ming Yin

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Targeting the ubiquitin-proteasome degradation pathway has become a promising approach for cancer therapy. Previous studies have shown that proteasome inhibition leads to apoptosis in various cancer cells. The mechanism by which apoptosis occurs are not fully understood and can be cell type and/or inhibitor specific. In this study, we investigated the mechanism of mitochondrial activation by proteasome inhibitors in colon cancer cells. We found that Bax activation and mitochondria translocation were required for apoptosis induced by multiple proteasome inhibitors. In contrast, reactive oxygen species did not seem to be induced by MG132 or bortezomib and antioxidants had no effects on MG132-induced apoptosis. In contrast, treatment with MG132 or bortezomib induced a significant accumulation of p53 and PUMA. Genetic deletion of either p53 or PUMA led to a marked suppression of apoptosis induced by these inhibitors, accompanied with reduced Bax activation and cytochrome c release. Consistently, inhibition of translation by cycloheximide could also effectively abolish the accumulation of p53 and PUMA and suppress MG132-induced Bax activation and apoptosis. These findings thus strongly indicate the critical involvement of p53-, PUMA-, and Bax-mediated mitochondrial activation in proteasome inhibitor-induced apoptosis in colon cancer cells.

Original languageEnglish (US)
Pages (from-to)1062-1069
Number of pages8
JournalMolecular Cancer Therapeutics
Volume6
Issue number3
DOIs
StatePublished - Mar 2007
Externally publishedYes

Fingerprint

Colonic Neoplasms
Mitochondria
Apoptosis
Proteasome Inhibitors
Proteasome Endopeptidase Complex
Cycloheximide
Ubiquitin
Cytochromes c
benzyloxycarbonylleucyl-leucyl-leucine aldehyde
Reactive Oxygen Species
Neoplasms
Antioxidants

ASJC Scopus subject areas

  • Oncology
  • Drug Discovery
  • Pharmacology

Cite this

A coordinated action of Bax, PUMA, and p53 promotes MG132-induced mitochondria activation and apoptosis in colon cancer cells. / Ding, Wen Xing; Ni, Hong Min; Chen, Xiaoyun; Yu, Jian; Zhang, Lin; Yin, Xiao-Ming.

In: Molecular Cancer Therapeutics, Vol. 6, No. 3, 03.2007, p. 1062-1069.

Research output: Contribution to journalArticle

Ding, Wen Xing ; Ni, Hong Min ; Chen, Xiaoyun ; Yu, Jian ; Zhang, Lin ; Yin, Xiao-Ming. / A coordinated action of Bax, PUMA, and p53 promotes MG132-induced mitochondria activation and apoptosis in colon cancer cells. In: Molecular Cancer Therapeutics. 2007 ; Vol. 6, No. 3. pp. 1062-1069.
@article{ebe1aca90a024fdf95902a77741c5bce,
title = "A coordinated action of Bax, PUMA, and p53 promotes MG132-induced mitochondria activation and apoptosis in colon cancer cells",
abstract = "Targeting the ubiquitin-proteasome degradation pathway has become a promising approach for cancer therapy. Previous studies have shown that proteasome inhibition leads to apoptosis in various cancer cells. The mechanism by which apoptosis occurs are not fully understood and can be cell type and/or inhibitor specific. In this study, we investigated the mechanism of mitochondrial activation by proteasome inhibitors in colon cancer cells. We found that Bax activation and mitochondria translocation were required for apoptosis induced by multiple proteasome inhibitors. In contrast, reactive oxygen species did not seem to be induced by MG132 or bortezomib and antioxidants had no effects on MG132-induced apoptosis. In contrast, treatment with MG132 or bortezomib induced a significant accumulation of p53 and PUMA. Genetic deletion of either p53 or PUMA led to a marked suppression of apoptosis induced by these inhibitors, accompanied with reduced Bax activation and cytochrome c release. Consistently, inhibition of translation by cycloheximide could also effectively abolish the accumulation of p53 and PUMA and suppress MG132-induced Bax activation and apoptosis. These findings thus strongly indicate the critical involvement of p53-, PUMA-, and Bax-mediated mitochondrial activation in proteasome inhibitor-induced apoptosis in colon cancer cells.",
author = "Ding, {Wen Xing} and Ni, {Hong Min} and Xiaoyun Chen and Jian Yu and Lin Zhang and Xiao-Ming Yin",
year = "2007",
month = "3",
doi = "10.1158/1535-7163.MCT-06-0541",
language = "English (US)",
volume = "6",
pages = "1062--1069",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - A coordinated action of Bax, PUMA, and p53 promotes MG132-induced mitochondria activation and apoptosis in colon cancer cells

AU - Ding, Wen Xing

AU - Ni, Hong Min

AU - Chen, Xiaoyun

AU - Yu, Jian

AU - Zhang, Lin

AU - Yin, Xiao-Ming

PY - 2007/3

Y1 - 2007/3

N2 - Targeting the ubiquitin-proteasome degradation pathway has become a promising approach for cancer therapy. Previous studies have shown that proteasome inhibition leads to apoptosis in various cancer cells. The mechanism by which apoptosis occurs are not fully understood and can be cell type and/or inhibitor specific. In this study, we investigated the mechanism of mitochondrial activation by proteasome inhibitors in colon cancer cells. We found that Bax activation and mitochondria translocation were required for apoptosis induced by multiple proteasome inhibitors. In contrast, reactive oxygen species did not seem to be induced by MG132 or bortezomib and antioxidants had no effects on MG132-induced apoptosis. In contrast, treatment with MG132 or bortezomib induced a significant accumulation of p53 and PUMA. Genetic deletion of either p53 or PUMA led to a marked suppression of apoptosis induced by these inhibitors, accompanied with reduced Bax activation and cytochrome c release. Consistently, inhibition of translation by cycloheximide could also effectively abolish the accumulation of p53 and PUMA and suppress MG132-induced Bax activation and apoptosis. These findings thus strongly indicate the critical involvement of p53-, PUMA-, and Bax-mediated mitochondrial activation in proteasome inhibitor-induced apoptosis in colon cancer cells.

AB - Targeting the ubiquitin-proteasome degradation pathway has become a promising approach for cancer therapy. Previous studies have shown that proteasome inhibition leads to apoptosis in various cancer cells. The mechanism by which apoptosis occurs are not fully understood and can be cell type and/or inhibitor specific. In this study, we investigated the mechanism of mitochondrial activation by proteasome inhibitors in colon cancer cells. We found that Bax activation and mitochondria translocation were required for apoptosis induced by multiple proteasome inhibitors. In contrast, reactive oxygen species did not seem to be induced by MG132 or bortezomib and antioxidants had no effects on MG132-induced apoptosis. In contrast, treatment with MG132 or bortezomib induced a significant accumulation of p53 and PUMA. Genetic deletion of either p53 or PUMA led to a marked suppression of apoptosis induced by these inhibitors, accompanied with reduced Bax activation and cytochrome c release. Consistently, inhibition of translation by cycloheximide could also effectively abolish the accumulation of p53 and PUMA and suppress MG132-induced Bax activation and apoptosis. These findings thus strongly indicate the critical involvement of p53-, PUMA-, and Bax-mediated mitochondrial activation in proteasome inhibitor-induced apoptosis in colon cancer cells.

UR - http://www.scopus.com/inward/record.url?scp=34147115711&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34147115711&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-06-0541

DO - 10.1158/1535-7163.MCT-06-0541

M3 - Article

C2 - 17363499

AN - SCOPUS:34147115711

VL - 6

SP - 1062

EP - 1069

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 3

ER -